Results 61 to 70 of about 485 (159)

Pharmacokinetics and pharmacodynamics of new acute treatments for migraine

open access: yes, 2019
Introduction: Recommended medications for the acute treatment of migraine encompass triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and analgesics.
Lupi, Chiara   +4 more
core   +1 more source

Recent Advances in the Management of Cluster Headache

open access: yes, 2020
Purpose of review: Among the spectrum of pain conditions, cluster headache represents one of the most severe. Targeted therapies for cluster headache are evolving thus improving the available therapeutic armamentarium.
Villar-Martínez, María Dolores   +5 more
core   +1 more source

Pathophysiology of Migraine: A Disorder of Sensory Processing. [PDF]

open access: yes, 2017
Plaguing humans for more than two millennia, manifest on every continent studied, and with more than one billion patients having an attack in any year, migraine stands as the sixth most common cause of disability on the planet.
Jan Hoffmann   +20 more
core   +3 more sources

Integrating new migraine treatments into clinical practice (part 1) : management of acute migraine attack.

open access: yes, 2023
editorial reviewedAlthough migraine is one of the most common chronic diseases and is the subject of numerous studies, there is still a considerable proportion of patients who are not satisfied with their acute treatment.
Fumal, A, Timmermans, Grégory
core  

Novel synthetic treatment options for migraine

open access: yes, 2020
Introduction: Migraine is one of the most common neurological disorders. Nowadays, the 5-HT1B/1D receptor agonists, namely triptans, are considered as the standard of care for migraine acute treatment. However, triptans have limitations in some patients,
Martelletti P.   +3 more
core   +1 more source

24-month outcomes after switching to Dolutegravir/Lamivudine in people living with HIV and HBcAb positivity at the Beijing Ditan Hospital in China

open access: yesAnnals of Medicine
Dolutegravir/lamivudine (DTG/3TC) is a recommended therapy regimen for hepatitis B surface antigen (HBsAg)-negative people living with HIV (PLWH) who have achieved HIV virological suppression or are treatment-naïve. However, this may overlook the impact of occult hepatitis B infection on HIV suppression, which mainly present as hepatitis B core ...
Jiantao Fu   +4 more
openaire   +3 more sources

Lasmiditan: new drug for acute migraine [PDF]

open access: yes, 2019
Migraine is ranked by the World Health Organization as the world’s second leading cause of disability. The current state of knowledge suggests that migraine is a neuronal process involving activation and sensitization of the trigeminal nociceptors and ...
Brashier, Dick   +5 more
core   +1 more source

Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review

open access: yes, 2021
Purpose: This narrative review provides an update on the research that led to the development of ditans and lasmiditan for the acute treatment of migraine in adults and discusses the potential advantages and disadvantages of lasmiditan in clinical use ...
Ferrari, Anna   +3 more
core   +1 more source

Therapeutic mechanisms of metformin and Bushen Ditan Decoction in polycystic ovary syndrome: Evidence from a rat model and miRNA sequencing

open access: yesJournal of Biological Methods
Background: Polycystic ovary syndrome (PCOS) represents the most common endocrine disorder afflicting women of reproductive age. PCOS is characterized by hormonal imbalances, metabolic abnormalities, and infertility, yet only limited therapeutic options are available.
Jiayi Xu   +4 more
openaire   +1 more source

Migraine: advances in treatment.

open access: yes
Increased understanding of the pathophysiology of migraine has resulted in the development of therapies targeting calcitonin gene-related peptide and its receptor.
Ashraf, Usman, Goadsby, Peter J
core   +1 more source

Home - About - Disclaimer - Privacy